Advanced Lectures in Clinical Immunology & Cellular Therapeutics
Welcome to Immunology board & ImmunoTACT We are immunologists from all over the world. We'll cover topics in lab& clinical immunology, with emphasis in pathogenesis, diagnosis & advanced immune cell therapies for hem/oncology @DrAkbarpourM @ImmunoTACT
إظهار المزيد- المشتركون
- التغطية البريدية
- ER - نسبة المشاركة
جاري تحميل البيانات...
جاري تحميل البيانات...
IntroductionPancreatic cancer is a truculent disease with limited treatment options and a grim prognosis. Immunotherapy has shown promise in treating various types of cancer, but its effectiveness in pancreatic cancer has been lacking. As a result, it is crucial to identify markers associated with immunological pathways in order to improve the treatment outcomes for this deadly cancer. The purpose of this study was to investigate the diagnostic and prognostic significance of three markers, CD8, CD68, and VISTA, in pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer.MethodsWe analyzed gene expression data from Gene Expression Omnibus (GEO) database using bioinformatics tools. We also utilized the STRING online tool and Funrich software to study the protein-protein interactions and transcription factors associated with CD8, CD68, and VISTA. In addition, tissue microarray (TMA) and immunohistochemistry (IHC) staining were performed on 228 samples of PDAC tissue and 10 samples of…
This study is the first to examine the applicability of BCL-2 inhibition in the setting of active HIV infection in vivo. Furthermore, this study demonstrates that venetoclax significantly enhances target cell killing induced by Fas ligand, TRAIL, and ...
Scientific Reports - Residual serum fibrinogen as a universal biomarker for all serotypes of Myasthenia gravis
The absence of B and T cells protects mice from pathogenesis by mouse-adapted SARS-CoV-2 MA10 despite elevated virus.
A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. Results were published today in Nature Medicine.
The emergence of Omicron lineages and descendent subvariants continues to present a severe threat to the effectiveness of vaccines and therapeutic ...
Activation of distinct myeloid signaling pathways converges to overcome immune suppression in pancreatic cancer.
Adding toripalimab (Loqtorz) to chemo extended survival in people with nasopharyngeal cancer that returned after initial treatment or spread in the body.
These FDA approvals display a relentless pursuit of innovation in oncology, empowering oncologists with increasingly sophisticated treatment to help navigate and manage cancer’s complexities.
Advancing cancer research is vital to find new cancer treatments. Learn about 23 cancer researchers made at MD Anderson during its Fiscal Year 2023.
تسمح خطتك الحالية بتحليلات لما لا يزيد عن 5 قنوات. للحصول على المزيد، يُرجى اختيار خطة مختلفة.